Biomea Fusion

Biomea Fusion

Biotechnology Research

Downtown Redwood City, California 4,753 followers

We are creating an entirely new Generation of Precision Medicine against Genetically Defined Diseases.

About us

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers. The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Downtown Redwood City, California
Type
Public Company
Founded
2017
Specialties
Biotech, Oncology, Patient Friendly Therapies , Targeted Medicine , Cancer Treatment, Acute Myeloid Leukemia, MLL Fusion, Diabetes Mellitus, Liquid Tumors, Solid Tumors, Innovative Medicine , Novel Mechanism of Action, Menin, and Irreversible Inhibitors

Locations

  • Primary

    900 Middlefield Rd

    4th Floor

    Downtown Redwood City, California 94063, US

    Get directions

Employees at Biomea Fusion

Updates

Similar pages

Browse jobs

Funding

Biomea Fusion 2 total rounds

Last Round

Post IPO equity

US$ 150.0M

See more info on crunchbase